Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice

被引:18
作者
Badillo-Godinez, O. [1 ,2 ]
Gutierrez-Xicotencatl, L. [3 ]
Plett-Torres, T. [3 ]
Pedroza-Saavedra, A. [3 ]
Gonzalez-Jaimes, A. [3 ]
Chihu-Amparan, L. [3 ]
Maldonado-Gama, M. [3 ]
Espino-Solis, G. [5 ]
Bonifaz, L. C. [4 ]
Esquivel-Guadarrama, F. [1 ]
机构
[1] UAEM, Lab Inmunidad Viral, Fac Med, Cuernavaca, Morelos, Mexico
[2] UAEM, Fac Ciencias, Cuernavaca, Morelos, Mexico
[3] CISEI Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico
[4] Hosp Siglo XXI, Unidad Inmunohistoquim, CMN, Mexico City, DF, Mexico
[5] UNAM, Inst Biotecnol, Cuernavaca, Morelos, Mexico
关键词
Rotavirus; VP6; Dendritic cells; DEC-205; Immunization; Vaccines; DENDRITIC CELL-RECEPTOR; INTRANASAL IMMUNIZATION; IMMUNE-RESPONSES; T-CELLS; ANTIGEN PRESENTATION; DNA VACCINE; PROTEIN; MUCOSAL; CHALLENGE; MURINE;
D O I
10.1016/j.vaccine.2015.03.080
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rotavirus (RV) is the primary etiologic agent of severe gastroenteritis in human infants. Although two attenuated RV-based vaccines have been licensed to be applied worldwide, they are not so effective in low-income countries, and the induced protection mechanisms have not been clearly established. Thus, it is important to develop new generation vaccines that induce long lasting heterotypic immunity. VP6 constitutes the middle layer protein of the RV virion. It is the most conserved protein and it is the target of protective T-cells; therefore, it is a potential candidate antigen for a new generation vaccine against the RV infection. We determined whether targeting the DEC-205 present in dendritic cells (DCs) with RV VP6 could induce protection at the intestinal level. VP6 was cross-linked to a monoclonal antibody (mAb) against murine DEC-205 (alpha DEC-205:VP6), and BALB/c mice were inoculated subcutaneously (s.c.) twice with the conjugated containing 1.5 mu g of VP6 in the presence of polyinosinic-polycytidylic acid (Poly I:C) as adjuvant. As controls and following the same protocol, mice were immunized with ovalbumin (OVA) cross-linked to the mAb anti-DEC-205 (alpha DEC-205:OVA), VP6 cross-linked to a control isotype mAb (Isotype:VP6), 3 mu g of VP6 alone, Poly I:C or PBS. Two weeks after the last inoculation, mice were orally challenged with a murine RV. Mice immunized with alpha-DEC-205:VP6 and VP6 alone presented similar levels of serum Abs to VP6 previous to the virus challenge. However, after the virus challenge, only alpha-DEC-205:VP6 induced up to a 45% IgA-independent protection. Memory T-helper (Th) cells from the spleen and the mesenteric lymph node (MLN) showed a Th1-type response upon antigen stimulation in vitro. These results show that when VP6 is administered parenterally targeting DEC-205, it can induce protection at the intestinal level at a very low dose, and this protection may be Th1-type cell dependent. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4228 / 4237
页数:10
相关论文
共 49 条
  • [1] Rotavirus vaccines: recent developments and future considerations
    Angel, Juana
    Franco, Manuel A.
    Greenberg, Harry B.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2007, 5 (07) : 529 - U18
  • [2] Banos DM, 1997, J VIROL, V71, P419
  • [3] IgA is important for clearance and critical for protection from rotavirus infection
    Blutt, S. E.
    Miller, A. D.
    Salmon, S. L.
    Metzger, D. W.
    Conner, M. E.
    [J]. MUCOSAL IMMUNOLOGY, 2012, 5 (06) : 712 - 719
  • [4] Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance
    Bonifaz, L
    Bonnyay, D
    Mahnke, K
    Rivera, M
    Nussenzweig, MC
    Steinman, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) : 1627 - 1638
  • [5] In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
    Bonifaz, LC
    Bonnyay, DP
    Charalambous, A
    Darguste, DI
    Fujii, SI
    Soares, H
    Brimnes, MK
    Moltedo, B
    Moran, TM
    Steinman, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) : 815 - 824
  • [6] ANALYSES OF HOMOLOGOUS ROTAVIRUS INFECTION IN THE MOUSE MODEL
    BURNS, JW
    KRISHNANEY, AA
    VO, PT
    ROUSE, RV
    ANDERSON, LJ
    GREENBERG, HB
    [J]. VIROLOGY, 1995, 207 (01) : 143 - 153
  • [7] Lymphocyte homing and homeostasis
    Butcher, EC
    Picker, LJ
    [J]. SCIENCE, 1996, 272 (5258) : 60 - 66
  • [8] Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses
    Choi, AH
    McNeal, MM
    Basu, M
    Flint, JA
    Stone, SC
    Clements, JD
    Bean, JA
    Poe, SA
    VanCott, JL
    Ward, RL
    [J]. VACCINE, 2002, 20 (27-28) : 3310 - 3321
  • [9] The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant
    Choi, AH
    McNeal, MM
    Flint, JA
    Basu, M
    Lycke, NY
    Clements, JD
    Bean, JA
    Davis, HL
    McCluskie, MJ
    VanCott, JL
    Ward, RL
    [J]. VACCINE, 2002, 20 (13-14) : 1733 - 1740
  • [10] Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G)
    Choi, AHC
    Smiley, K
    Basu, M
    [J]. VACCINE, 2005, 23 (17-18) : 2290 - 2293